BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30449176)

  • 1. Promising positive liver targeting delivery system based on arabinogalactan-anchored polymeric micelles of norcantharidin.
    Zhang Z; Yang L; Hou J; Xia X; Wang J; Ning Q; Jiang S
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S630-S640. PubMed ID: 30449176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
    Jiang S; Li M; Hu Y; Zhang Z; Lv H
    Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
    Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
    Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.
    Guan M; Zhou Y; Zhu QL; Liu Y; Bei YY; Zhang XN; Zhang Q
    Nanomedicine; 2012 Oct; 8(7):1172-81. PubMed ID: 22321383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells.
    Liang L; Zhao L; Wang Y; Wang Y
    Mol Pharm; 2021 Mar; 18(3):1003-1013. PubMed ID: 33527831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
    Ren J; Li G; Zhao W; Lin L; Ye T
    World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells.
    Ding Z; Xu B; Zhang H; Wang Z; Sun L; Tang M; Ding M; Zhang T; Shi S
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization and anticancer activity of norcantharidin-loaded poly(ethylene glycol)-poly(caprolactone) amphiphilic block copolymer micelles.
    Chen SF; Lu WF; Wen ZY; Li Q; Chen JH
    Pharmazie; 2012 Sep; 67(9):781-8. PubMed ID: 23016451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
    Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
    Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
    Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and pharmacological evaluation of norcantharidin-conjugated carboxymethyl chitosan in mice bearing hepatocellular carcinoma.
    Jiang Z; Chi J; Han B; Liu W
    Carbohydr Polym; 2017 Oct; 174():282-290. PubMed ID: 28821069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis.
    Yan Z; Yang K; Tang X; Bi Y; Ding Y; Deng M; Xia D; Zhao Y; Chen T
    J Immunol Res; 2022; 2022():3851604. PubMed ID: 35497873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte-targeted delivery using ph-sensitive liposomes loaded with lactosylnorcantharidin phospholipid complex: preparation, characterization, and therapeutic evaluation in vivo and in vitro.
    Qiao-ling Z; Yi Z; Min G; Di-jia Y; Xiao-feng Z; Yang L; Jing-yu X; Ying W; Zong-lin G; Kong-lang X; Ai-jun Z; Wei-liang C; Lin-sen S; Xue-nong Z; Qiang Z
    Curr Med Chem; 2012; 19(33):5754-63. PubMed ID: 22963621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
    Xie MH; Ge M; Peng JB; Jiang XR; Wang DS; Ji LQ; Ying Y; Wang Z
    Pharm Dev Technol; 2019 Jun; 24(5):623-629. PubMed ID: 30457414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
    Jin X; Mo R; Ding Y; Zheng W; Zhang C
    Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norcantharidin combined with Coix seed oil synergistically induces apoptosis and inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation.
    Wang D; Yang C; Wang Z; Yang Y; Li D; Ding X; Xu W; Zheng Q
    Sci Rep; 2017 Aug; 7(1):9373. PubMed ID: 28839202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
    Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
    Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on the liver targeting of norcantharindin microemulsion].
    Zhang L; Xiang D; Hong Z; Zhang ZR
    Yao Xue Xue Bao; 2004 Aug; 39(8):650-5. PubMed ID: 15563071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
    Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
    Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.